Alexion Pharmaceuticals Inc (NASDAQ: ALXN)

ALXN 0.00
182.50 (100.0%)

TR N
10 x 0.00 = 0
x $0.00 =

ALXN Profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Website

YouTube Symbol Surfing

Watch these videos to learn how Symbol Surfing can increase your trading and investing knowledge and results.